A Phase 3 interventional study of Normobaric Hyperoxia and Nasal oxygen in Acute Ischemic Stroke, sponsored by Ji Xunming,MD,PhD. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-28.
Sponsored by Ji Xunming,MD,PhD · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 753 studies in Ischemic Stroke with a site in China — 380 open to participants now, 399 under way, 78 of them phase 3. Ischemic Stroke · China.
Among the 753 studies in Ischemic Stroke with a site in China, this one is the 75th largest by planned enrollment of the 565 interventional ones that give a count, is one of 92 that started in 2023, is one of 111 in phase 3, reaches primary completion later than 60 of the 398 other live ones, and was the 366th registered.
2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.
Browse Ischemic Stroke studies →380 of the 753 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:
Xidian University · Sites in China
Ages 18+
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18+
Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Sites in China
Ages 18–85
Yongjun Wang · Sites in China
Ages 18+
Shandong Provincial Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
753 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 110 · Phase 3 136 · Phase 4 70
First in 2000; this study’s year is marked. 92 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,230 is above the median of 120 across 1,785 interventional studies indexed under Ischemic Stroke.
Median enrollment 270 across the 565 interventional studies, 625 across the 188 observational. Of the 235 that completed or were terminated, 10 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 753 have an industry lead sponsor. The 10 most frequent:
Ji Xunming,MD,PhD is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
Ji Xunming,MD,PhD has 9 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
109 of the studies in Ischemic Stroke with a site in China that are under way reach primary completion within a year, 23 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559241Phase 3Capital Medical UniversityRemote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy(RECAST-MT) | 2026-11 |
| NCT06615726Phase 3Capital Medical UniversityRegular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis | 2026-11-19 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06749834Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityIntravenous Thrombolysis and NOAC | 2026-12-31 |
| NCT07335107Phase 3Beijing Tiantan HospitalIntravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion | 2027-01-31 |
Add all 109 to your calendar (.ics) → With an account.
Among the 753 studies in Ischemic Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the long-term efficacy and safety of Normobaric Hyperoxia combined with intravenous thrombolysis for acute ischemic stroke.
In this study, cases of acute ischemic stroke who undergo intravenous thrombolysis within 4.5 hours from onset are included. The Normobaric Hyperoxia(NBO) group receive basic intravenous thrombolysis and given 100% oxygen inhalation at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. The control group receive basic intravenous thrombolysis and given oxygen inhalation at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. The investigators aimed to determine the long-term effect of Normobaric Hyperoxia combined with intravenous thrombolysis for acute ischemic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Normobaric Hyperoxia combined with intravenous thrombolysis
Device: Normobaric Hyperoxia · Drug: Intravenous thrombolysis(rt-PA)
Nasal oxygen combined with intravenous thrombolysis
Device: Nasal oxygen · Drug: Intravenous thrombolysis(rt-PA)
Within 4.5 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 10L/ min using a sealed non-ventilating oxygen storage mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.
For nasal oxygen group, Patients were immediately given oxygen inhalation (no more than 30 minutes after randomization) at a ventilation rate of 1L/min using nasal cannula and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%.
10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.
Utility-weighted modified Rankin scale scores
Utility-weighted modified Rankin scale scores
Time frame: 12 months±14 days after randomization
Cerebral infarct volume
The infarct volume of cerebral infarct is evaluated by MRI
Time frame: 24-48hours after randomization
modified Rankin Scale (mRS) score
Ordinal distribution of mRS at 12 months±14 days after randomization; mRS score ranges from 0 to 5, and the higher score means a worse outcome
Time frame: 12 months±14 days after randomization
Good functional outcome
Proportion of subjects with modified rankin scale (mRS) 0-2 at 12 months±14 days after randomization
Time frame: 12 months±14 days after randomization
Excellent functional outcome
Proportion of subjects with modified Rankin Scale (mRS) 0-1 at 6 months±14 days after randomization; mRS score ranges from 0 to 5, and the higher score means a worse outcome
Time frame: 6 months±14 days after randomization
Good functional outcome
Proportion of subjects with modified rankin scale (mRS) 0-2 at 6 months±14 days after randomization
Time frame: 6 months±14 days after randomization
modified Rankin Scale (mRS) score
Ordinal distribution of mRS at 6 months±14 days after randomization; mRS score ranges from 0 to 5, and the higher score means a worse outcome
Time frame: 6 months±14 days after randomization
Scores assessed by National Institutes of Health Stroke Scale(NIHSS)
Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 to 42, with higher scores indicating more severe neurologic deficits
Time frame: 4 ± 2 hours, 24 ± 6 hours, 72 ± 24 hours, 7 ± 2 days after randomization
Barthel Index (BI)
The BI is an ordinal disability score of 10 categories (range from 0 to 100, higher values indicate better prognosis)
Time frame: 6 months±14 days,12 months±14 days after randomization
EuroQol five dimensions questionnaire(EQ-5D)
The score ranges from 0 to 100, with higher scores indicating optimal health
Time frame: 6 months±14 days,12 months±14 days after randomization
Stroke-related mortality
Safety endpoint; the proportion of stroke related deaths in each group
Time frame: 12 months±14 days after randomization
All-cause mortality
Safety endpoint; the proportion of all patients who died in each group
Time frame: 12 months±14 days after randomization
Symptomatic intracranial hemorrhage
Proportion of subjects with symptomatic intracranial hemorrhage at 24 ± 6 hours after randomization (defined by ECASSII and ECASS III)
Time frame: 24 ± 6 hours after randomization
Asymptomatic intracranial hemorrhage
The incidence of asymptomatic intracranial hemorrhage at 24 ± 6 hours after randomization
Time frame: 24 ± 6 hours after randomization
PH2 intracranial hemorrhage
The incidence of PH2 intracranial hemorrhage at 24 ± 6 hours after randomization (according to SITS standards)
Time frame: 24 ± 6 hours after randomization
Adverse events/serious adverse events
Safety endpoint; the proportion of adverse events/serious adverse events in each group
Time frame: 24 ± 12 hours, 7 ± 2 days, 90± 7 days, 6 months±14 days,12 months±14 days after randomization
Excellent functional outcome
Proportion of subjects with modified Rankin Scale (mRS) 0-1 at 12 months±14 days after randomization; mRS score ranges from 0 to 5, and the higher score means a worse outcome
Time frame: 12 months±14 days after randomization
Started Aug 2023 (actual). Primary completion is estimated for Aug 2025, 24 months after the start.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 24 months is below that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ji Xunming,MD,PhD